Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,660 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
R-High-CHOP/CHASER/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY.
Ogura M, Yamamoto K, Morishima Y, Wakabayashi M, Tobinai K, Ando K, Uike N, Kurosawa M, Gomyo H, Taniwaki M, Nosaka K, Tsukamoto N, Shimoyama T, Fukuhara N, Yakushijin Y, Ohnishi K, Miyazaki K, Sawada K, Takayama N, Hanamura I, Nagai H, Kobayashi H, Usuki K, Kobayashi N, Ohyashiki K, Utsumi T, Kumagai K, Maruyama D, Ohmachi K, Matsuno Y, Nakamura S, Hotta T, Tsukasaki K; Japan Clinical Oncology Group- Lymphoma Study Group (JCOG-LSG). Ogura M, et al. Among authors: nagai h. Cancer Sci. 2018 Sep;109(9):2830-2840. doi: 10.1111/cas.13719. Epub 2018 Jul 28. Cancer Sci. 2018. PMID: 29957865 Free PMC article. Clinical Trial.
CD56/NCAM-positive Langerhans cell sarcoma: a clinicopathologic study of 4 cases.
Kawase T, Hamazaki M, Ogura M, Kawase Y, Murayama T, Mori Y, Nagai H, Tateno M, Oyama T, Kamiya Y, Taji H, Kagami Y, Naoe T, Takahashi T, Morishima Y, Nakamura S. Kawase T, et al. Among authors: nagai h. Int J Hematol. 2005 May;81(4):323-9. doi: 10.1532/IJH97.04142. Int J Hematol. 2005. PMID: 15914364
[Malignant lymphoma].
Nagai H, Hotta T. Nagai H, et al. Nihon Rinsho. 2007 Jan 28;65 Suppl 1:80-5. Nihon Rinsho. 2007. PMID: 17474397 Review. Japanese. No abstract available.
Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Ohmachi K, Ando K, Ogura M, Uchida T, Itoh K, Kubota N, Ishizawa K, Yamamoto J, Watanabe T, Uike N, Choi I, Terui Y, Usuki K, Nagai H, Uoshima N, Tobinai K; Japanese Bendamustine Lymphoma Study Group. Ohmachi K, et al. Among authors: nagai h. Cancer Sci. 2010 Sep;101(9):2059-64. doi: 10.1111/j.1349-7006.2010.01635.x. Cancer Sci. 2010. PMID: 20626754 Free PMC article. Clinical Trial.
Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma.
Nagai H, Ogura M, Kusumoto S, Takahashi N, Yamaguchi M, Takayama N, Kinoshita T, Motoji T, Ohyashiki K, Kosugi H, Matsuda S, Ohnishi K, Omachi K, Hotta T. Nagai H, et al. Eur J Haematol. 2011 Feb;86(2):117-23. doi: 10.1111/j.1600-0609.2010.01552.x. Epub 2010 Dec 29. Eur J Haematol. 2011. PMID: 21070370 Clinical Trial.
2,660 results